Sun Pharmaceutical Industries Limited appears to have a mixed financial health. The company's strengths include high gross margins (79.56%) and a decent profit margin (20.79%), indicating efficient operations. However, the company's weaknesses include a high debt-to-equity ratio (3.259) and negative earnings growth (-18.8%). The valuation seems rich, with a trailing P/E of 36.48 and a forward P/E of 50.85. Overall, while the company has some operational efficiencies, its high debt and poor earnings growth are concerns, and the valuation may be stretched.